7.2 Plain-Language Summaries and Patient Partnership
Key Takeaways
A plain-language summary of a publication should communicate the same study accurately for its intended non-specialist audience, with balanced benefits, harms, limitations, and uncertainty.
GPP 2022 supports considering patient involvement and accessible publication formats, but it does not make patient partnership at study inception or a PLSP a universal requirement for every publication.
No single school-grade target applies to every PLSP; use audience research, venue guidance, plain-language principles, readability diagnostics, and user review rather than treating a score as proof of comprehension.
EU clinical-trial results summaries for laypersons are regulatory submissions distinct from optional journal PLSPs; the applicable regulation, CTIS guidance, trial status, and deadlines govern them.
Patients and advocates can be authors when they satisfy all four ICMJE criteria and may receive reasonable compensation for legitimate advisory work, never for authorship status or favorable conclusions.
Plain-Language Summaries and Patient Partnership
A plain-language summary of a publication (PLSP) explains a peer-reviewed work for people who may not share the authors' technical training. Its purpose is access to the same science, not simplification into advertising. The intended audience may include patients, caregivers, advocates, non-specialist clinicians, policymakers, or the public, and their information needs may differ.
Preserve the scientific meaning
A defensible PLSP reports the research question, participants, methods, main findings, important harms, limitations, and what the study can and cannot establish. Numerical results should keep useful denominators, absolute effects, time frames, and uncertainty. “The risk fell by 50%” is incomplete if the actual change was from 2 in 1,000 to 1 in 1,000. “No significant difference” should not be rewritten as “the treatments were the same.”
Avoid promotional superlatives such as “revolutionary,” “breakthrough,” “miracle,” or “completely safe.” A summary linked to an industry-funded study should identify funding, writing support, and conflicts as required by the venue. It should not add claims, audiences, subgroup conclusions, or comparisons absent from the parent work.
Useful drafting practices include:
- define technical terms at first use and use a consistent term thereafter;
- favor short, direct sentences and active constructions where accuracy permits;
- use headings, white space, lists, and visual explanations to reduce cognitive load;
- explain randomization, comparator, endpoints, and uncertainty in concrete language;
- use natural frequencies and absolute effects when useful;
- report important adverse events and discontinuations, not benefits alone;
- distinguish association from causation and exploratory from prespecified results;
- provide accessible formats and meaningful alternative text for visuals.
Readability is a diagnostic, not a mandate
Flesch Reading Ease, Flesch–Kincaid Grade Level, SMOG, and similar tools count features such as sentence length and syllables. They can reveal dense prose, but they do not measure factual accuracy, health literacy, cultural fit, visual accessibility, or whether a reader understood the message. Medical terms can inflate a grade score even when well explained.
There is no universal GPP rule that every PLSP must fall between US grades 6 and 8. The appropriate target depends on the audience, venue, language, condition, legal requirements, and local guidance. Use a stated target when a journal, funder, regulator, or organization supplies one. Otherwise, document the intended audience, use readability tools as diagnostics, and seek review from representative readers where feasible.
Translation also requires more than word substitution. Use qualified translation and cultural adaptation processes appropriate to the risk, and verify numbers, terminology, labels, and layout after translation. Back translation can be useful in some workflows but is not a universal guarantee of quality.
Patient involvement
Patients and caregivers can improve topic prioritization, outcome relevance, terminology, visual design, interpretation, dissemination channels, and accessibility. Meaningful involvement starts with a defined purpose and an opportunity to influence decisions. It should not be tokenistic or used to manufacture endorsement.
GPP 2022 encourages consideration of patients as publication partners and audiences. It does not state that every publication must include a patient at study inception or that every article must have a PLSP. Plan involvement at a stage when it can matter, disclose roles, provide training or support, address accessibility, and explain how feedback was handled. Protect participants from pressure to reveal health details or publicly endorse a product.
Authorship, acknowledgment, and compensation
Patient status neither qualifies nor disqualifies a contributor from authorship. Apply the same four ICMJE criteria: substantial contribution; drafting or critical intellectual revision; final approval; and accountability. Someone who advises on terminology but does not meet all criteria may be acknowledged, with permission, and their contribution can be described.
Reasonable compensation for legitimate advisory time, preparation, accessibility needs, travel, childcare, or other agreed expenses may reduce barriers to participation. Use a written agreement and a defensible rate or policy. Compensation must not purchase authorship, favorable interpretation, silence about harms, or journal acceptance. Disclose relevant relationships under applicable policies.
Regulatory lay summaries are different
A journal PLSP should not be confused with a clinical-trial results summary for laypersons required under the EU Clinical Trials Regulation for trials within its scope. The regulatory summary is submitted through the Clinical Trials Information System and is governed by the regulation and current implementing guidance, including applicable timing and content rules. A journal PLSP is an editorial publication feature unless a journal, funder, or other policy makes it required.
One document does not automatically replace the other. They may have different data cutoffs, templates, audiences, review processes, identifiers, and timing. The team should map each obligation to the correct source and keep the scientific story consistent.
A review checklist
Before release, ask:
- Who is the intended reader, and was that audience involved in review where feasible?
- Do all numbers, denominators, time points, comparators, and conclusions match the source?
- Are benefits, harms, limitations, and uncertainty balanced?
- Does the summary avoid promotional language and unsupported causal claims?
- Are authorship, contributor roles, funding, and writing support handled transparently?
- Does the format meet venue and accessibility requirements?
- Are translation, privacy, consent, and local regulatory needs addressed?
- Is this a journal PLSP, a regulatory lay summary, or both as separate deliverables?
Tip
When an exam option treats a grade-level score as the only quality test, reject it. Prefer an accurate, audience-tested, accessible summary whose language and layout follow the controlling venue or regulatory requirement.
A PLSP calls a therapy “revolutionary” and “free of meaningful adverse effects,” reports only a relative risk reduction, and has a high readability grade. What should the reviewer request?
Keep the claims because plain language permits persuasive wording.
Remove all numbers so readers are not confused.
Shorten the words but retain the benefit-only message.
Replace promotional claims with source-matched language; present useful absolute and relative context, harms, limitations, and uncertainty; and revise with the intended audience and venue guidance in mind.
A patient advocate shaped outcome selection, co-drafted the discussion, critically revised it, approved the final version, and accepts accountability. How should authorship and compensation be handled?
Apply the four ICMJE criteria like any other contributor; authorship is appropriate if all are met, and reasonable payment for legitimate advisory work may be made under an agreement without paying for authorship or outcomes.
A patient can only be acknowledged because authors must be clinicians.
Offer authorship only if the advocate waives reimbursement.
Pay an acceptance bonus because journal publication proves the contribution was valuable.
What best distinguishes an EU regulatory lay summary from a journal PLSP?
The regulatory summary is promotional, while the PLSP is scientific.
The regulatory summary is a required CTIS deliverable for trials within the regulation’s scope under applicable rules, while a journal PLSP is an editorial publication format unless another policy requires it.
A journal PLSP always satisfies the regulatory obligation.
Only the regulatory summary may mention adverse events.
Sections you finish are checked off in the contents.